Bixiye
QP74-23 Commercial Pharmacy Benefit Exclusion for Abilify Asimtufii®, Adstiladrin®, Brixadi™, Glydo®, lidocaine 2%, Roctavian™, and Uzedy™
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 13, 2023
Dukumentiyadda & Foomamka Natiijooyinka
Soo bandhiga 1161 - 1170 ee natiijooyinka 3563
Bixiye
QP75-23 MHCP Pharmacy Benefit Exclusion for Adstiladrin®, Brixadi™, and Roctavian™
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 13, 2023
Bixiye
QP76-23 Commercial Pharmacy Benefit Exclusion for Sublocade®
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 13, 2023
Bixiye
P59-23 Services Removed from the Commercial Prior Authorization List
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 01, 2023
Bixiye
P60-23 Home Health Agencies are Required to Provide Minnesota Home Care Bill of Rights for Clients
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 01, 2023
Bixiye
P61-23 Inpatient Hospital Admission Prior Authorization Removed for Medicare Advantage; Pre-Admission Notification Required
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 01, 2023
Bixiye
P62-23 eviCore Healthcare Specialty Utilization Management (UM) Program: Medical Oncology Drug Prior Authorization Updates
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 01, 2023
Bixiye
P63-23 New Medical, Medical Drug and Behavioral Health Policy Management Updates: Effective November 6, 2023
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 01, 2023
Bixiye
P65-23 eviCore Healthcare Specialty Utilization Management (UM) Program: Radiation Oncology Clinical Guideline Updates
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 01, 2023
Bixiye
P66-23 Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans managed by Blue Cross and Blue Shield of Alabama
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 01, 2023